glp-1 shortage canada news today CPHA: Now Second-Largest User Market Globally 3 million Canadians use GLP-1

Retrieved from Monfort, A., Macente, J., Van Neste, M., et al

During a session on stage, CVS Health Chief Technology Officer Tilak Mandadi told me that Cuban's claims about PBMs are "bulls--t," pointing to savings on generic drugs that the company offers employers through TrueCost

Frequency unknown: Angioedema, back pain, cutaneous vasculitis, interstitial lung disease, joint disorders, myalgia, pancreatitis, renal impairment, StevensJohnson syndrome, hepatic function abnormalities

Ambrish Mithal, Chairman & Head, Endocrinology & Diabetes, Max Healthcare, explained what GLP-1 drugs mean for diabetes and obesity management and how they work